FDA meeting cancelled
This article was originally published in The Tan Sheet
A meeting of FDA's Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology scheduled for April 30 has been cancelled, the agency says April 5. The meeting was planned to discuss issues pertaining to the stability of tablets split for patient use (1"The Tan Sheet" March 12, 2007, In Brief). Also on April 5, FDA says the meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology scheduled for May 1-2 is cancelled...
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.